ArticleJournal of molecular histology2026
miR-196a-5p affects the progression of polycystic ovary syndrome by targeting EPHA7.
Article in Journal of molecular histology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Polycystic ovary syndrome (PCOS), a highly prevalent endocrine disorder in women of reproductive age, is strongly associated with infertility. This study explored the relevance of the regulation of KGN cell function by miR-196a-5p and the pathogenesis of PCOS. This study selected 105 patients with non-obese, hyperandrogenic PCOS and 88 healthy individuals as research subjects. The levels of miR-196a-5p and EPHA7 in cells were assayed by RT-qPCR. Diagnostic accuracy of miR-196a-5p for PCOS was analyzed by ROC curve and multivariate logistic regression analysis. Chi-square test was used to analyze the correlation between the differential expression of miR-196a-5p and clinical indicators. Cell proliferation and apoptosis were assayed by CCK8 and flow cytometry. Western blot was used to detect the expression of apoptosis-related proteins and EPHA7 protein. Relationship between EPHA7 and miR-196a-5p was detected through miRDB database and dual-luciferase reporter assay. Correlation between miR-196a-5p and EPHA7 in non-obese, hyperandrogenic PCOS patients was analyzed by Pearson correlation. In GCs from non-obese, hyperandrogenic PCOS patients, an up-regulation of miR-196a-5p levels was observed, while EPHA7 showed a down-regulation trend. ROC analysis showed that miR-196a-5p had a high diagnostic value for non-obese, hyperandrogenic PCOS patients. miR-196a-5p may be an independent risk factor for PCOS, and it is significantly positively correlated with clinical indicators. Overexpression of miR-196a-5p in KGN cells enhanced cell proliferation and reduced apoptosis, while inhibition of this miRNA expression reversed this effect. In PCOS, miR-196a-5p was negatively correlated with EPHA7. Furthermore, reducing EPHA7 levels counteracted the regulatory effects of miR-196a-5p downregulation on KGN cells. miR-196a-5p was upregulated in GCs from non-obese, hyperandrogenic PCOS patients and promoted cell proliferation and inhibited apoptosis by regulating EPHA7. Therefore, miR-196a-5p shows promise as a novel biomarker and therapeutic target for this subtype of PCOS.
Indexed as
Identifiers
42018244What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.